Prognia
Drug Database
🇺🇸US · FDA ApprovedNone (Tentative Approval)ANDA210391-003

ABACAVIR, DOLUTEGRAVIR, LAMIVUDINE

Integrase inhibitors; Antivirals for treatment of HIV infections, combinations; Nucleoside and nucleotide reverse transcriptase inhibitors

Manufacturer: CIPLA LIMITED

FDA Approval: 30/06/2025

Active Ingredients

ABACAVIR, DOLUTEGRAVIR, LAMIVUDINE 300MG

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about ABACAVIR, DOLUTEGRAVIR, LAMIVUDINE — check interactions with your patient's full medication list, get dosing recommendations with renal/hepatic adjustments, and explore guideline-cited evidence.

Medical disclaimer: This drug information is intended for qualified healthcare professionals only. Always verify with the official FDA prescribing information before clinical use.